Citation only
via OpenAlex
Chronic Mechanistic Target of Rapamycin Inhibition: Preventing Cancer to Delay Aging, or Vice Versa?
Zelton Dave Sharp, Tyler Jay Curiel, Carolina Becker Livi
Interdisciplinary topics in gerontology and geriatrics · 2013 · ▲ 12 citations
Abstract
Cancer and aging appear to be inexorably linked, yet approaches to ameliorate them in concert are lacking. Although not (easily) feasible in humans, years of preclinical research show that diet and growth factor restriction each successfully address cancer and aging together. Chronic treatment of genetically heterogeneous mice with an enteric formulation of mTOR(definition)-inhibiting drug studied for extending healthspan and lifespan." style="text-decoration:underline dotted; text-underline-offset:2px; cursor:help;">rapamycin(definition) (eRapa) extended maximum lifespan of both genders when started in mid or late life. In part, cancer amelioration in treated mice suggested that long-term eRapa, like diet restriction, could be a pharmacological approach feasible for use in the clinic. We review the current understanding of the role of the mechanistic target of rapamycin (mTOR) in cancer and aging. We also discuss the tumor immune surveillance system, and the need for a better understanding of its responses to mTOR inhibitors. We also address the issue of the misperception that rapamycin is a potent immunosuppressant. Finally, we review the current state of mTOR inhibitors in the cancer clinic. Because of the burgeoning elderly population most at risk for cancer, there is a great need for our eRapa findings to be a proof of concept for the development of new and more comprehensive approaches to cancer prevention that are safe and also mitigate other deleterious effects of aging.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1159/000343625
- Canonical
- link ↗
- Fetched
- 2026-10-07 MST
Cite this
APA
Sharp, Z.D., Curiel, T.J., & Livi, C.B. (2013). Chronic Mechanistic Target of Rapamycin Inhibition: Preventing Cancer to Delay Aging, or Vice Versa?. <em>Interdisciplinary topics in gerontology and geriatrics</em>. https://doi.org/10.1159/000343625
Vancouver
Sharp ZD, Curiel TJ, Livi CB. Chronic Mechanistic Target of Rapamycin Inhibition: Preventing Cancer to Delay Aging, or Vice Versa?. Interdisciplinary topics in gerontology and geriatrics. 2013. doi:10.1159/000343625.
BibTeX
@article{zelton2013Chroni,
title = {Chronic Mechanistic Target of Rapamycin Inhibition: Preventing Cancer to Delay Aging, or Vice Versa?},
author = {Zelton Dave Sharp and Tyler Jay Curiel and Carolina Becker Livi},
journal = {Interdisciplinary topics in gerontology and geriatrics},
year = {2013},
doi = {10.1159/000343625},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Springer eBooks 2020
Citation only
Chronic Mechanistic Target of Rapamycin Inhibition: Preventing Cancer to Delay Aging or Vice Versa?
Springer eBooks 2017
Citation only
Chronic Mechanistic Target of Rapamycin Inhibition: Preventing Cancer to Delay Aging or Vice Versa?
Frontiers in Immunology 2018
Open access · CC-BY
Immunosenescence and Inflamm-Aging As Two Sides of the Same Coin: Friends or Foes?
Cancer Plus 2026
Open access · CC-BY
Viral latency as a driver of epigenetic clock dysregulation and immune aging in cancer development
JNCI Journal of the National Cancer Institute 2008
Citation only
Understanding Pathways of Calorie Restriction: A Way To Prevent Cancer?
University Hospital, Brest 2018
Open access · US-GOV